Thursday , November 23 2017
Home / Specialties / Nephrology / Dr. Matthew Weir Part 1, SGLT2 Drugs and Kidney Disease

Dr. Matthew Weir Part 1, SGLT2 Drugs and Kidney Disease

Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the impact of SGLT2 drugs on the possible improvement of kidney disease.

Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine at the University of Maryland. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. 

Return to main page.